

Resource Summary Report

Generated by NIF on Jul 28, 2026

CD14 APC MOP9 CE

RRID:AB_2868813

Type: Antibody

Proper Citation

BD Biosciences Cat# 345787, RRID:AB_2868813

Antibody Information

URL: http://antibodyregistry.org/AB_2868813

Proper Citation: BD Biosciences Cat# 345787, RRID:AB_2868813

Target Antigen: CD14

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD14 APC MOP9 CE

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: M?P9

Antibody ID: AB_2868813

Vendor: BD Biosciences

Catalog Number: 345787

Record Creation Time: 20250820T012548+0000

Record Last Update: 20250820T105441+0000

Ratings and Alerts

No rating or validation information has been found for CD14 APC MOP9 CE.

No alerts have been found for CD14 APC MOP9 CE.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Träger C, et al. (2025) A probiotic approach identifies a Treg-centred immunoregulation via modulation of gut microbiota metabolites in people with multiple sclerosis and healthy individuals. EBioMedicine, 116, 105743.

Van der Meer JMR, et al. (2024) Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer. Cytotherapy, 26(2), 136.

van Houtum EJH, et al. (2023) Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7. Cellular and molecular life sciences : CMLS, 80(6), 169.

Hiemstra IH, et al. (2023) Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine, 93, 104663.